Degree of control and delayed intensification of antihyperglycaemic treatment in type 2 diabetes mellitus patients in primary care in Spain

Diabetes Research and Clinical Practice

Volumn 91, Issue 1, 2011, Pages 108-114

  Conthe, Pedro ^a   Mata, Manuel ^b   Orozco, Domingo ^c   Pajuelo, Francisco ^d   Barreto, Carmen Sofía ^d   Anaya, Silvia Fernández ^d   Gomis, Ramón ^e  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b ABS la Mina   (Spain)

^c CS San Blas   (Spain)

^d MSD   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Combination therapy; Intensification; Monotherapy; Primary care; T2DM

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTICLE; BODY MASS; CEREBROVASCULAR DISEASE; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; SPAIN; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVENTIVE HEALTH SERVICES; RETROSPECTIVE STUDIES; SPAIN; TIME FACTORS; YOUNG ADULT;

EID: 78650538582     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.10.002     Document Type: Article

References (25)

1. Manley S. Haemoglobin A1c-a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 2003, 41:1182-1190.
2. Gerstein H.C., Miller M.E., Byington R.P., Goff D.C., Bigger J.T., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(June (24)). Action to Control Cardiovascular Risk in Diabetes Study Group, 2545-59.3.
3. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(June (24)). ADVANCE Collaborative Group, 2560-72.4.
4. American Diabetes Association (ADA): Standards of medical care in diabetes-2009. Diabetes Care 2009:32(Suppl. 1): S13-S61.
5. NICE (National Institute for Health and Clinical Excellence). Clinical guideline CG87. Type 2 diabetes: the management of type 2 diabetes (partial update may 2009) Disponible en: (last access november 27th 2009). http://guidance.nice.org.uk/CG87/NiceGuidance/pdf/English.
6. Brown J.B., Nichols G.A., Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004, 27(7):1535-1540.
7. Mateo J.F., Gil-Guillén V.F., Mateo E., Orozco D., Carbayo J.A., Merino J. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract 2006, 60(April (4)):422-428. [PubMed PMID: 16620354].
8. Van Bruggen R., Gorter K., Stolk R., Klungel O., Rutten G. Clinica inertia in general practice: widespread and related to the outcomes of diabetes care. Fam Pract 2009, September. [Epub ahead of print].
9. Safford M.M., Shewchuk R., Qu H., Williams J.H., Estrada C.A., Ovalle F., et al. Reasons for not intensifying medications: differentiating "clinical inertia" from appropriate care. J Gen Intern Med 2007, 22:1648-1655.
10. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26(3):881-885.
11. American Association of Clinical Endocrinologist (AACE) Diabetes Mellitus Clinical Practice Guidelines Task Force. AACE medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13 Suppl 1:1-68.
12. Rydén L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M.J., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007, 28(1):88-136.
13. Levy J., Atkinson A.B., Bell P.M., McCance D.R., Hadden D.R. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Care 1998, 15:290-296.
14. Turner R.C., Cull C.A., Frighi V. Glycaemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012. Holman RR for the UK Prospective Diabetes Study (UKPDS) Group.
15. Nathan D.M., Buse J.B., Davidson M.B., Ferrannini E., Holman R.R., Sherwin R., et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
16. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006; 23(6):579-93.
17. Blonde L. State of diabetes care in the United States. Am J Manag Care 2007, 13:S36-S40.
18. Yood M.U., Lafata J.E., Koro C., Wells K.E., Pladevall M. Time to pharmacotherapy change in response to elevated HbA1c test results. Curr Med Res Opin 2006, 22(8):1567-1574.
19. Nichols G.A., Koo Y.H., Shah S.N. Delay of insulin addition to oral combination therapy despite inadequate glycaemic control: delay of insulin therapy. J Gen Intern Med 2007 Apr, 22(4):453-458.
20. Orozco-Beltrán D., Gil-Guillen V.F., Quirce F., Navarro-Perez J., Pineda M., Gomez-de-la-Cámara A., et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. Int J Clin Pract 2007, 61:909-915.
21. Benito-López P., García-Mayor R., Puig-Domingo M., Mesa-Manteca J., Palelardo-Sánchez L.F., Faure-Nogueras E., et al. Perfil de los pacientes con Diabetes Mellitus tipo 2, en la Atención Primaria española. Rev Clin Esp 2004, 204(1):18-24.
22. Arroyo J., Badía X., De la Calle H., Díez J., Esmatjes E., Fernández I., et al. Tratamiento de los pacientes con diabetes mellitus tipo 2 en atención primaria en España. Med Clin (Barc) 2005, 125(5):166-172.
23. Ortiz Tobarra M.T., Orozco Beltrán D., Gil Guillén V., Terol Moltó C. Frequency of attendance and degree of control of type-2 diabetic patients. Aten Primaria 2008, 40:139-144.
24. Liebl A., Mata M., Eschwège E. CODE-2 Advisory Board. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002, 45(7):S23-S28.
25. Ray K.K., Seshasai S.R., Wijesuriya S., Sivakumaran R., Nethercott S., Preiss D., Erqou S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trial. Lancet 2009, 373:1765-1772.